新潟大学皮膚科特別セミナー

日時：2025年9月10日（水）18：00～

＊Zoomにて開催します。

My early career years of clinical research in tuberous sclerosis complex

Department of Dermatology, Kaohsiung Veterans General Hospital, Taiwan

Prof. Chien-Hui Hong

I did my research fellowship in a combined program of NHLBI and USUHS 20 years ago. This program initiates my early career of scientific research in the field of tuberous sclerosis complex. My study began with a clinical and translational focus on mucocutaneous and systemic manifestations of the disease. I conducted nationwide epidemiological studies using Taiwan's National Health Insurance database, revealing the increasing prevalence and incidence of TSC, as well as identifying late diagnosis as a key prognostic factor for higher mortality. Clinically, I contributed to defining diagnostic criteria by highlighting the predictive value of cutaneous features—such as ungual fibromas and forehead plaques—for CNS involvement. Our lab also demonstrated mTOR activation in TSC skin lesions and uncovered the role of MCP-1 in tumorigenesis. These foundational efforts established a comprehensive approach to understanding, diagnosing, and treating TSC across disciplines. I am invited to write an editorial regarding the clinical trial for the ambient-stable topical rapamycin cream for treating angiofibromas in TSC. I hope this talk will help harvest the passion for young physicians for academic tract amid the work and life balance.

1. Hong CH, Lee CH. Ambient-stable topical rapamycin cream is effective in treating angiofibromas in tuberous sclerosis complex. *Br J Dermatol* 2023;189(5):507-508.
2. Hong CH, Lee CH. A nationwide UK cohort study reveals an association between atopic dermatitis and venous thromboembolism. *Br J Dermatol*. 2023;189(4):363-364.